BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20230101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240521
DTEND;VALUE=DATE:20240524
DTSTAMP:20260516T013746
CREATED:20240208T111843Z
LAST-MODIFIED:20240208T112145Z
UID:38632-1716249600-1716508799@www.pharmajournalist.com
SUMMARY:6th Annual Treg-Directed Therapies Summit
DESCRIPTION:Driving Next Gen Treg Stimulation for Autoimmunity\, Transplantation & Inflammation \nReturning to Boston for its 6th year\, the 6th Treg-Directed Therapies Summit stands as the singular industry forum shining a spotlight on the groundbreaking research and clinical advancements in CAR-Treg and IL2 mutein therapies. Witness the convergence of leading industry and academic experts as they unite to propel the clinical efficacy of Treg therapies to new heights. \nAs the pioneering and longest-tenured meeting dedicated to optimizing and manipulating Treg-based approaches\, this summit invites you to become part of a community at the forefront of innovation. Gain unparalleled insights into the latest developments driving specificity\, delve into novel cell product design\, and explore the engineering of CAR-Tregs to enhance cell stability and durability. \nDon’t miss this unique opportunity to stay ahead in the dynamic landscape of Treg therapies. Join us and contribute to the ongoing dialogue that shapes the future of cutting-edge medical advancements. \nTo know more visit: https://ter.li/gfpnb0
URL:https://www.pharmajournalist.com/event/6th-annual-treg-directed-therapies-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240522
DTEND;VALUE=DATE:20240525
DTSTAMP:20260516T013746
CREATED:20240103T113206Z
LAST-MODIFIED:20240103T113206Z
UID:38410-1716336000-1716595199@www.pharmajournalist.com
SUMMARY:5th Gene Therapy Analytical Development Europe Summit
DESCRIPTION:The 5th Gene Therapy Analytical Development Europe – What to Expect in 2024? \nIn the face of evolving regulatory guidelines and mounting scrutiny\, the 5th Gene Therapy Analytical Development Europe Summit will discuss ways you can apply contemporary analytical tools to guarantee the consistency\, quality\, and safety of your gene therapy products. \nJoin leading CMC\, regulatory\, QC\, analytical and process development experts to gain access to novel data and recent case studies by industry professionals from AstraZeneca\, the MHRA\, Novartis\, Sarepta Therapeutics\, Roche\, Sanofi\, and many more. \nEnjoy in-depth\, valuable networking opportunities with scientists and senior decision makers from small biotech through to large pharma – perfect for those looking to further industry relationships. \nTo know more visit: https://ter.li/vz0jr4
URL:https://www.pharmajournalist.com/event/5th-gene-therapy-analytical-development-europe-summit/
LOCATION:15Hatfields\, Chadwick Court\, London\, SE1 8DJ\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240529
DTEND;VALUE=DATE:20240601
DTSTAMP:20260516T013746
CREATED:20240117T112916Z
LAST-MODIFIED:20240119T121741Z
UID:38533-1716940800-1717199999@www.pharmajournalist.com
SUMMARY:4th Gene Therapy Patient Engagement Summit
DESCRIPTION:Patient engagement is a crucial responsibility of any gene therapy company if they’re serious about progressing safe\, effective\, and meaningful therapies to patients. The 4th Gene Therapy Patient Engagement Summit is returning in 2024\, sitting at the unique interface of patient engagement and gene therapy\, from embarking on first in-human trials through to commercial therapeutics. \nDelve into key challenges including engaging in R&D and managing expectations of gene therapies\, language and nomenclature used to educate on what gene therapies are and what it means to participate in a clinical trial\, outlining informed consent to support clinical trial enrollment\, and understanding the latest regulatory requirements to effectively demonstrate that these transformative therapies are meaningful to patients. \nJoin 80+ patient advocacy and engagement professionals from gene therapy companies and patient advocacy groups to gain actionable insights that you can immediately implement into your own gene therapy programs. Unite with the leading voices in this community to develop solutions to the challenges that are unique to the gene therapy space. \nTo learn more and discover the full agenda\, visit the official event website at genetherapy-patient-engagement.com
URL:https://www.pharmajournalist.com/event/4th-gene-therapy-patient-engagement-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240604
DTEND;VALUE=DATE:20240607
DTSTAMP:20260516T013746
CREATED:20240219T105830Z
LAST-MODIFIED:20240219T105830Z
UID:38732-1717459200-1717718399@www.pharmajournalist.com
SUMMARY:Computational RNA Design & Delivery Summit
DESCRIPTION:AI and computational science are revolutionizing the field of RNA therapeutic discovery\, which is empowering biopharma companies to harness the potential of this technology. Join the conversation at the world’s first industry-dedicated Computational RNA Design & Delivery Summit taking place in Boston this June 4 – 6 2024. \nHear what industry pioneers from Sanofi\, Moderna\, Nava Therapeutics\, Nutcracker Therapeutics\, and more have to say\, and deep dive into harnessing AI\, Machine learning\, deep neural networks\, and predictive algorithms for RNA design and delivery to scale and accelerate novel\, cost-effective RNA-based therapeutics. \nHere’s a snapshot of the speaker faculty: \n\nMihir Mektar\, Principal Scientist\, Moderna\nSarah Spencer\, Senior Expert II Data Science\, Novartis\nBenjamin Mead\, Principal Data Scientist\, Nava Therapeutics\nDinghai Zheng\, Machine Learning Senior Scientist\, Sanofi\nEvan McCartney-Melstad\, Director of Bioinformatics\, Nutcracker Therapeutics\nKelly Brock\, Senior Computational Biologist\, Kernal Biologics\n\nThis exclusive meeting has been designed with you in mind! Join 80+ data science\, computational biology/chemistry\, bioinformatic\, and delivery experts to accelerate discovery of your mRNA\, RNAi\, and tRNA modalities and innovate the delivery of these modalities beyond the liver by deep-diving into LNP\, peptide-based\, and AAV delivery chemistry. \nBook your place now\, early birds are still available!
URL:https://www.pharmajournalist.com/event/computational-rna-design-delivery-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240610
DTEND;VALUE=DATE:20240613
DTSTAMP:20260516T013746
CREATED:20240215T112047Z
LAST-MODIFIED:20240215T112047Z
UID:38716-1717977600-1718236799@www.pharmajournalist.com
SUMMARY:6th Allogeneic Cell Therapies Summit
DESCRIPTION:The entire cell therapy field is experiencing a shift towards allogeneic platforms as the potential to achieve a truly off-the-shelf\, universal\, and efficacious cell therapy offers great advantages such as reduced cost\, production and patient accessibility compared to its autologous counterparts. \nPlacing a spotlight on what has been deemed the ‘future of cell therapy’\, the 6th Annual Allogeneic Cell Therapies Summit returns to Boston this June as the leading industry focused meeting dedicated to accelerating the safety\, durability and clinical translation of off-the-shelf therapies to deliver affordable and accessible treatments for patients in critical need. \nAcross a jam-packed agenda consisting of 60+ hours of content\, 3 in-depth tracks\, 1 Investor & Business Development Focus Day\, 1 Beyond Oncology Bootcamp Day and more; our 50+ expert speakers will lead you and your peers in discussions that will help to transform universal cell therapies for patients across the globe. \nLearn more here: https://ter.li/aetc0d
URL:https://www.pharmajournalist.com/event/6th-allogeneic-cell-therapies-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240610
DTEND;VALUE=DATE:20240612
DTSTAMP:20260516T013746
CREATED:20240502T125908Z
LAST-MODIFIED:20240502T125908Z
UID:39043-1717977600-1718150399@www.pharmajournalist.com
SUMMARY:Pre-Filled Syringes West Coast
DESCRIPTION:SAE Media Group’s 8th Annual Pre-Filled Syringes West Coast Conference will be back for 2024 in the West Coast to bring together device developers\, biotech and big pharma. This year’s conference will explore the exciting advances in the combination product drug delivery space and a future outlook exploring how pharma\, device developers and regulators can work together to encourage innovation. \n \nAs part of SAE’s leading injectable drug delivery conferences this is a must attend event; not only will the conference bring you key insights to enhance your drug device portfolio\, but it will also give you the opportunity to network with key industry players. We hope to welcome you in June 2024! \nWhat will you gain? \n\nEngage in discussions on evolving EU and US regulations as well as reviewing the latest FDA guidance on human factors and drawing insights from successful notified body opinions for streamlined regulatory compliance.\nGain insight into advancements in large volume drug delivery devices with a case study from Halozyme and a panel discussion assessing key considerations\, benefits and barriers of such devices for stakeholders including patients\, HCPs and pharma companies.\nDelve into comprehensive strategies for maximizing combination product manufacturing and effectively managing your product’s lifecycle with key insights from GSK and Merck\nAcquire insights into human factors best practices from AbbVie and Regeneron\, and discover ways to effectively apply testing and validation approaches for combination products.\nExplore collaborative opportunities to advance innovation in the injectables field and gain insight into the latest technology updates and challenges these pose such as leaching in electro-mechanical devices.
URL:https://www.pharmajournalist.com/event/pre-filled-syringes-west-coast-2024/
LOCATION:SAN DIEGO MARRIOTT LA JOLLA\, 4240 La Jolla Village Drive\, La Jolla\, San Diego\, CA\, 92037\, United States
ORGANIZER;CN="SAE Media Group":MAILTO:EVENTS@SAEMEDIAGROUP.COM
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240611
DTEND;VALUE=DATE:20240614
DTSTAMP:20260516T013746
CREATED:20240208T112624Z
LAST-MODIFIED:20240208T112624Z
UID:38638-1718064000-1718323199@www.pharmajournalist.com
SUMMARY:3rd Process Development for Cell Therapies Summit
DESCRIPTION:Driving Process Robustness\, Scalability\, Speed & Affordability \nIn the dynamic cell therapy landscape\, where financial challenges continue to prevail\, the emphasis on innovative process development becomes pivotal. Now\, more than ever\, there’s a heightened demand for cost-effective solutions that bolster scalability and expedite development timelines. \nWelcome to the 3rd Process Development for Cell Therapies Summit\, your paramount gathering dedicated to advancing process robustness\, scalability\, speed\, and affordability. This ensures the rapid advancement of highly efficacious products through clinical trials\, securing a market-ready status with competitive commercial viability. \nWhether you’re on the brink of IND or gearing up for BLA submission\, this gathering of brilliant minds offers an unparalleled opportunity to glean insights form organizations like BMS\, Beam Therapeutics\, 2seventy Bio\, Takeda\, Century Therapeutics\, AstraZeneca\, and more! \nSeize this opportunity to connect with technical experts united in the goal of streamlining process development. Through the sharing of best practices and pre-competitive insights\, let’s collectively drive the streamlined development of consistent\, scalable\, and cost-effective autologous and allogeneic cell therapies. Together\, we can shape the future of cell therapy! \nTo know more visit: https://ter.li/ixkr7z
URL:https://www.pharmajournalist.com/event/3rd-process-development-for-cell-therapies-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240611
DTEND;VALUE=DATE:20240614
DTSTAMP:20260516T013746
CREATED:20240208T113943Z
LAST-MODIFIED:20240222T125925Z
UID:38641-1718064000-1718323199@www.pharmajournalist.com
SUMMARY:Structure-Based Drug Design Summit
DESCRIPTION:Harnessing Integrative Structural Biology Techniques Including NMR\, X-Ray Crystallography\, Cryo-EM\, & Cryo-ET to Determine 3D Structures of Pharmacologically Relevant Targets & Propel Drug Design \nHave you heard the boom created by Cryo-EM? Drug development has been shaken up with the application of Cryo-EM\, accelerating and increasing the rate of success of protein targeting by identifying new ways to treat diseases with greater sensitivity and efficiency in the study of 3D structures. Structural biologists\, medicinal chemists\, and computational chemists need to assess the experimental methods by sharing case study presentations to streamline\, rationalize\, and optimize drug design. \nThe inaugural Structure-Based Drug Design Summit  is your opportunity to assess the resolution and speed of the techniques in the toolbox to answer structural biology questions for drug design\, assess the gaps\, and implement newer techniques for increased specificity and precision \nSharing cutting-edge structural biology methods and applications\, including harnessing Cryo-EM and Cryo-ET to visualize protein interactions\, structure-based methods as a package of techniques to study integrated biological systems\, and incorporating computational methods as a predictive tool for structures; this is a unique opportunity to come together and rationalize drug design by understanding the 3D structure of proteins. Join 50+ industry scientists to delve into 3D protein structure determination using NMR\, X-Ray Crystallography\, Cryo-EM\, and Cryo-ET\, to improve resolution and efficiency and rationalize drug development. \nRevolutionize the way drugs are discovered and developed to lead to newer and more effective therapeutics for a wide range of diseases\, build the complete 3D picture\, and go after undruggable targets.
URL:https://www.pharmajournalist.com/event/structure-based-drug-design-summit/
LOCATION:Embassy Suites by Hilton Boston at Logan Airport\, 207 Porter St\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240611
DTEND;VALUE=DATE:20240614
DTSTAMP:20260516T013746
CREATED:20240321T115006Z
LAST-MODIFIED:20240321T115126Z
UID:38904-1718064000-1718323199@www.pharmajournalist.com
SUMMARY:6th Age-Related Disease Therapeutics Summit
DESCRIPTION:The 6th Age-Related Disease Therapeutics Summit is returning to San Francisco in June\, with 60+ participants including Eli Lilly\, Takeda\, and Turn Biosciences to dive deep into breakthroughs in cellular programming\, senolytic pathways\, and epigenetic effects. Explore biomarkers\, navigate regulations\, and foster collaborations for pipeline support and commercialization. \nThis is your definitive age-related disease therapeutics forum to gain unparalleled competitive intelligence\, scientific advancements and form meaningful partnerships to solve humankind’s fundamental problem.
URL:https://www.pharmajournalist.com/event/6th-age-related-disease-therapeutics-summit/
LOCATION:Hyatt Centric Fisherman’s Wharf\, 555 North Point Street\, San Francsico\, CA\, 94133\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240612
DTEND;VALUE=DATE:20240615
DTSTAMP:20260516T013746
CREATED:20240410T111557Z
LAST-MODIFIED:20240411T111540Z
UID:38976-1718150400-1718409599@www.pharmajournalist.com
SUMMARY:4th Next Generation Gene Therapy Vectors Summit
DESCRIPTION:Accelerate your capsid and payload design with the 4th Next Generation Gene Therapy Vectors Summit (June 12-14\, Boston) \nAs a recent whitepaper by the Alliance for Regenerative Medicine cites capsid engineering and disruptive delivery platforms as key emerging technologies in the CGT space\, drug developers are heavily investing in finding and optimizing the safety\, efficacy\, and predictability of delivery platforms. \nThis is 2024’s only meeting covering the latest advances and innovations in vector development for gene therapies\, uniting 90+ R&D and business development leaders to advance cutting-edge delivery platforms into the clinic. Data-driven talks\, expert panels\, and interactive group discussions led by 25+ industry experts will provide you with the ‘latest and greatest’ in both disruptive viral and non-viral vectors. \nJoin us to gain actionable insights in how to enable targeted gene delivery\, reduce immunogenicity & toxicity\, enhance downstream manufacturability\, expand packaging capabilities\, and secure funding and investment for your own vector platform. \nWant to learn more? Check out the event guide here https://ter.li/nnkbb3
URL:https://www.pharmajournalist.com/event/4th-next-generation-gene-therapy-vectors-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240619
DTEND;VALUE=DATE:20240621
DTSTAMP:20260516T013746
CREATED:20240321T120430Z
LAST-MODIFIED:20240321T120754Z
UID:38919-1718755200-1718927999@www.pharmajournalist.com
SUMMARY:World CDx Regulatory Affairs & Policy Summit
DESCRIPTION:The highly anticipated World CDx Regulatory Affairs & Policy Summit\, is set to debut in Boston from June 19-20\, 2024. \nFrom tackling the complexities of LDT regulation and navigating the IVDR maze to understanding reimbursement dynamics\, this groundbreaking meeting promises to provide clarity and harmonization in the realm of CDx regulation. Attendance is FREE for drug developers and academics\, join us to maintain your clinical momentum\, streamline submissions\, overcome regulatory bottlenecks\, and improve patient access to companion diagnostics. \nWorld Class speakers you have the opportunity to learn from: \n\nVihanga Pahalawatta\, Director – Regulatory Affairs Companion Diagnostics\, AbbVie\nAndrea Renninger\, Senior Director – CDx Regulatory Affairs\, Daiichi Sankyo\nClaudia Dollins\, Vice President – Global Regulatory Affairs\, GSK\nDebra Rasmussen\, Senior Director – Global Regulatory Affairs\, Johnson & Johnson\nDun Liang – Executive Director\, Regulatory Affairs\, CDx\, Loxo@Lilly\nSiddhartha Mathur – Executive Director – Regulatory Affairs\, Merck\nQing Li\, Director – Pathology\, clinical development\, Oncology\, Moderna\nJai Pandey\, Global Head – Device Regulatory for In Vitro Diagnostics & Companion Diagnostics\, Digital Health\, Sanofi\n\nThis summit is poised to bring together key stakeholders\, including Directors\, VPs\, and SVPs in Regulation\, Policy\, Reimbursement\, Digital Health\, and Companion Diagnostics from leading companies as well as regulatory experts\, payers\, and developers to bridge the gap with clinical practice and ease regulatory pressures. Download the brochure or secure your free place now!
URL:https://www.pharmajournalist.com/event/world-cdx-regulatory-affairs-policy-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240625
DTEND;VALUE=DATE:20240628
DTSTAMP:20260516T013746
CREATED:20240223T112318Z
LAST-MODIFIED:20240223T112353Z
UID:38757-1719273600-1719532799@www.pharmajournalist.com
SUMMARY:Cell & Gene Therapy Pricing & Reimbursement Summit
DESCRIPTION:Cell and gene therapies are revolutionizing healthcare\, offering promising solutions from curative treatments to long-term remission rates. As these treatments enter the market\, ensuring fair access while addressing coverage and payment complexities becomes paramount. \n  Introducing the inaugural Cell & Gene Therapy Pricing & Reimbursement Summit. Biotech\, pharma\, physicians\, healthcare providers\, and regulatory and government agencies will unite to address key issues such as the impact of regulatory acts\, implementing pricing models\, and collaborating on enhanced reimbursement strategies\, aiming to expedite the availability of these advanced therapies to patients. \nWith the recent approval of Casgevy by Vertex Pharmaceuticals and CRISPR Therapeutics\, and Lyfgenia by bluebird bio; significant strides in healthcare have been made\, offering groundbreaking treatments with transformative potential\, yet presenting substantial cost challenges. The Inflation Reduction Act and new Cell and Gene Therapy (CGT) Access Model aim to address these cost concerns by proposing innovative pricing models and reimbursement strategies to ensure affordability and widespread access to these life-changing therapies. \n Join us this June to discuss the impacts of this legislation and together\, we will optimize patient access and propel the success of commercial cell and gene therapy launches. \nSee the full agenda here: https://ter.li/d1rn7b
URL:https://www.pharmajournalist.com/event/cell-gene-therapy-pricing-reimbursement-summit/
LOCATION:Marriott Washington Capitol Hill\, 175 L Street NE\, WA\, 20002\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240625
DTEND;VALUE=DATE:20240628
DTSTAMP:20260516T013746
CREATED:20240321T120048Z
LAST-MODIFIED:20240321T120048Z
UID:38913-1719273600-1719532799@www.pharmajournalist.com
SUMMARY:2nd mRNA Quality Control & Compliance Summit
DESCRIPTION:Regulatory guidelines and existing protocols to govern aspects of mRNA quality during development and manufacturing are still evolving\, creating a lack of clarity and consensus amongst the mRNA community. \nWithout a clear path forward\, drug developers risk comprising product quality\, safety and efficacy\, and so the 2nd mRNA Quality Control & Compliance Summit is back to Boston this June as the sole industry-centred forum dedicated to showcasing data and discussions on mRNA compliance and optimized documentation\, ensuring streamlined approval for mRNA therapeutics and vaccines! \nReuniting industry experts in quality control\, quality assurance\, analytical development\, and CMC\, this forum aims to navigate regulatory guidelines and identify tangible best practices towards optimized documentation\, discuss verification processes for platform methods and review method validation used to evaluate critical vaccine qualities\, all towards safeguarding faster mRNA drug approvals in line with regulatory expectations. \nDownload the free brochure or book your place now\, early birds are still available!
URL:https://www.pharmajournalist.com/event/2nd-mrna-quality-control-compliance-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240709
DTEND;VALUE=DATE:20240712
DTSTAMP:20260516T013746
CREATED:20240319T002431Z
LAST-MODIFIED:20240319T003018Z
UID:38869-1720483200-1720742399@www.pharmajournalist.com
SUMMARY:3rd In Vivo Cell Engineering & Gene Editing Summit
DESCRIPTION:Welcome to the Future of Cell & Gene Therapy \nThe 3rd In Vivo Cell Engineering & Gene Editing Summit is an annual event uniting C-level in vivo experts to facilitate safe and targeted in vivo delivery of payloads while providing clarity in regulations and appropriate models to advance the next frontier of in vivo editing from research to clinic. \nExplore the full agenda – https://ter.li/snxcxi \nAs promising pre-clinical and proof of concept results continue to emerge\, the ‘dream’ of in vivo cell engineering and gene editing is rapidly becoming a reality as numerous companies push towards the clinic. \nJoin us this July to network with and gain invaluable knowledge from our world-class speaker faculty from Capstan Therapeutics\, Editas Medicine\, NanoCell Therapeutics\, Carisma Therapeutics\, Sanofi\, and more\, offering exclusive insights into their strategies for staying ahead of the curve and shaping the future of cell and gene therapy in the years ahead. \nKey Highlights: \n\nExploring data-driven case studies to outline decision making when selecting viral versus non-viral vectors\nClarifying regulatory expectations for this novel therapeutic approach to map out the future of your pipeline\nBenchmarking appropriate preclinical models to support translation to gain valuable data needed by regulatory bodies\nOutlining the considerations when scaling up towards the clinic to equip you with the tools to tackle bottlenecks\nEmphasizing target specificity and the mitigation off-site toxicities to ensure safety is front of mind in development\n\nRegister now for the best savings – https://ter.li/ssnrpz \n#InVivoCellEngineeringandGeneEditingSummit
URL:https://www.pharmajournalist.com/event/3rd-in-vivo-cell-engineering-gene-editing-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240729
DTEND;VALUE=DATE:20240801
DTSTAMP:20260516T013746
CREATED:20240314T144151Z
LAST-MODIFIED:20240314T144151Z
UID:38832-1722211200-1722470399@www.pharmajournalist.com
SUMMARY:4th mRNA-Based Therapeutics Summit
DESCRIPTION:Fast-Track Your mRNA-Based Therapeutics & Vaccines from Discovery to Commercialization by Ensuring Targeted Delivery\, Durability & Tolerable Immunogenicity Across All Disease Indications \nAs mRNA developments continue to dominate industry news\, ranging from winning the Nobel Prize to new clinical candidates\, positive Phase I readouts and approvals\, the industry is set to reunite in Boston this July for the 4th mRNA-Based Therapeutics Summit. \nHear the latest unseen data from proof-of-concept studies\, platform development\, clinical updates and regulatory insights as 65+ world-class speakers take to the stage. With expert-led sessions by the likes of the FDA\, EMA\, Moderna\, BioNTech and Sanofi\, this year’s 4-track agenda will provide unmissable scientific and strategic insights into the biggest challenges faced in discovery\, translation\, clinical development\, and CMC. \n\nDates: July 29-31\, 2024\nLocation: Westin Boston Seaport District\, Boston\, MA\nEvent Program: https://ter.li/fezohk\n\nJoin the Next Generation mRNA Delivery or Regulatory Affairs Strategy focus days\, exchange business cards in Speed Networking\, quiz your peers in the Scientific Poster Session and have your voice heard during the Roundtable Discussions to maximize your experience at this year’s summit. \nDownload the agenda here: https://ter.li/fezohk \nRegister your place here (and take advantage of group discounts of up to 20% when sending your team of three or more!): https://ter.li/6vnq38
URL:https://www.pharmajournalist.com/event/4th-mrna-based-therapeutics-summit/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240729
DTEND;VALUE=DATE:20240801
DTSTAMP:20260516T013746
CREATED:20240409T112413Z
LAST-MODIFIED:20240409T112547Z
UID:38951-1722211200-1722470399@www.pharmajournalist.com
SUMMARY:5th Gamma Delta T Cell Therapies Summit
DESCRIPTION:The 5th Gamma Delta T Cell Therapies Summit will bring together experts from big pharma\, biotech and academia to delve into the details of gamma delta biology and its various subsets to offer the audience a well-rounded overview of the landscape currently and the steps needed for it to move forward. \nFind out more here: https://ter.li/yryaj1 \n \nWith a world-class speaker faculty sharing the latest insights in the field\, this meeting continues to be the one-stop shop to accelerate your gamma delta T therapies! Hear from IN8Bio\, Adicet Bio\, Acepodia\, Takeda\, Luminary Therapeutics\, LAVA Therapeutics\, OneChain Therapeutics and many more! \nAs the ONLY industry gamma delta T cell-specific meeting running this year\, these three days will expedite the translation of your vd1/vd2 pipelines from bench to bedside\, fostering prompt progress in the field. Take this opportunity to upskill your cross-functional team across discovery\, translation\, clinical development\, CMC and manufacturing to successfully translate basic research into your clinical strategy to support your IND submission. \nFind out more here: https://ter.li/yryaj1
URL:https://www.pharmajournalist.com/event/5th-gamma-delta-t-cell-therapies-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240820
DTEND;VALUE=DATE:20240823
DTSTAMP:20260516T013746
CREATED:20240423T145330Z
LAST-MODIFIED:20240423T145330Z
UID:39018-1724112000-1724371199@www.pharmajournalist.com
SUMMARY:2nd RNA Assay Development Screening Summit
DESCRIPTION:There has been many exciting investments and advancements in the field\, such as Atavistik Bio raising an additional $40 million to advance their small molecule therapeutics and Servier and Base4 expanding their partnership to accelerate development of neuroscience drugs. However\, the discovery of potent RNA targeting small molecules is plagued by limited robust assays and screening methods for understanding the RNA target structure as well as the mechanism of action of the small molecule drugs. \nHence\, this August the 2nd RNA Assay Development & Screening Summit returns to Boston as the first and only industry dedicated event on developing sensitive\, and reproducible assay and screening methods. With 70% brand new speaker faculty from key stakeholder companies as well as new companies entering the field\, including the likes of AstraZeneca\, Arrakis Therapeutics\, Molecure\, Wayfinder Biosciences\, Biogen and more\, access the latest strategies for developing reproducible and sensitive assay and screening methods. \nDownload the free brochure or book your place now\, early birds are still available!
URL:https://www.pharmajournalist.com/event/2nd-rna-assay-development-screening-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240820
DTEND;VALUE=DATE:20240823
DTSTAMP:20260516T013746
CREATED:20240515T095414Z
LAST-MODIFIED:20240515T095414Z
UID:39112-1724112000-1724371199@www.pharmajournalist.com
SUMMARY:5th Gene Therapy Immunogenicity Summit
DESCRIPTION:Optimize Safety & De-Risk Efficacy of Viral Vector-Based Gene Therapies \nThe success of gene therapy hinges on overcoming the immunogenicity challenges of viral vectors. With more viral vector-based gene therapies progressing through the pipeline\, we need to seek solutions to this critical bottleneck ‘here and now’. \nThe 5th Gene Therapy Immunogenicity Summit is returning to Boston this August\, bringing together 100+ immunogenicity experts responsible for predicting\, measuring\, and mitigating immune response. Join your colleagues as they share their learnings and gain key insights on: \n \n\nEffective approaches to promote AAV safety whilst maintaining efficacy\nPreventing the bottlenecks of the potential slowdown of gene therapy development\n\nAccess specific\, case-study-led examples across immunogenicity and ask the big-hitting immunology questions to your peers actively working in the space to make clinically safe and effective gene therapies a reality. \n\nPredicting and mitigating against complement activation and other toxicity issues with Ask Bio\, Takeda\, and Novartis\nValidating novel Immunoassays\, bioanalytical and biodistribution technology with Astellas Gene Therapies and Boehringer Ingelheim\nUnderstanding possible risks around exacerbation of both the innate and adaptive immune response with Roche and Tenaya Therapeutics\nExploring the practicalities of AAV redosing through an immunology lens with the University of Indiana and Adolore Biotherapeutics\nExamine the immunogenicity risks specific to gene editing approached as momentum in the field increases with CRISPR and Modalis Therapeutics
URL:https://www.pharmajournalist.com/event/5th-gene-therapy-immunogenicity-summit/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240820
DTEND;VALUE=DATE:20240823
DTSTAMP:20260516T013746
CREATED:20240523T112419Z
LAST-MODIFIED:20240529T133152Z
UID:39154-1724112000-1724371199@www.pharmajournalist.com
SUMMARY:2nd ADC Linker & Conjugation Summit
DESCRIPTION:With Eli Lilly’s acquisition of Mablink and Novartis’ investment in Tagworks\, both centering on their innovative linker and conjugation technologies – optimizing linker chemistry and diversifying conjugation technologies to increase stability and selectivity are becoming increasingly more attractive to ADC developers as they strive for a competitive edge over their peers. \n \nAs part of the World ADC Series\, the 2nd ADC Linker & Conjugation Summit is the only forum exclusively focused on enhancing your linker and conjugation chemistry. With 100+ attendees ranging from boots-on-the-ground scientists working on improving linker & conjugation chemistries daily\, through to more senior directors\, this conference is the optimal combination of knowledge sharing and networking. \nLeave this summit with the confidence to innovate hydrophilic linkers that help prevent aggregation\, enhance stability in linkers & conjugations to ensure tumor targeting and hone site-specific conjugations to guarantee homogenous DAR\, all to ultimately ensure ADC stability and widen therapeutic index.
URL:https://www.pharmajournalist.com/event/2nd-adc-linker-conjugation-summit/
LOCATION:W Boston\, 100 Stuart Street\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:adc@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240827
DTEND;VALUE=DATE:20240830
DTSTAMP:20260516T013746
CREATED:20240515T095016Z
LAST-MODIFIED:20240515T095016Z
UID:39106-1724716800-1724975999@www.pharmajournalist.com
SUMMARY:3rd Digital Biomarkers & Clinical Measures for Neurology Summit
DESCRIPTION:Delivering on the Promise of Precision Medicine with Digital Measures in Neurology \nHarnessing More Quantitative\, Objective & Less Invasive Measures to Reduce Costs & Improve Neurology Patient Experience \n2023 welcomed SV95C as the first ever digital endpoint qualified by a regulatory agency\, which means that the floodgates have now opened to the potential of digital biomarkers to transform clinical development in neurology. \nFrom the latest validated research on implementing speech\, cognition\, and motor tracking measures into clinical development\, to navigating the regulatory and commercial landscape\, the 3rd Digital Biomarkers & Clinical Measures for Neurology Summit is the ultimate platform to take your digital strategy to the next level. \nThis August\, join 80+ senior industry leaders across digital health\, medical affairs\, clinical development\, and regulatory this year from Biogen\, DEEP Measures\, Janssen\, Alexion Pharmaceuticals\, Eisai\, Pfizer\, Novo Nordisk\, Novartis\, Boehringer Ingelheim\, Takeda\, MTP\, BMS\, Alto Neurosciences\, Michael J. Fox Foundation\, Cerevel Therapeutics\, Regeneron and many more…
URL:https://www.pharmajournalist.com/event/3rd-digital-biomarkers-clinical-measures-for-neurology-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240827
DTEND;VALUE=DATE:20240830
DTSTAMP:20260516T013746
CREATED:20240730T144029Z
LAST-MODIFIED:20240730T144412Z
UID:39475-1724716800-1724975999@www.pharmajournalist.com
SUMMARY:3rd Oligonucleotide CMC & Analytical Development Summit
DESCRIPTION:Exclusively dedicated to uniting AD\, QC\, and CMC leaders the 3rd Oligonucleotide CMC & Analytical Development Summit is the only industry-led meeting solving your impurity\, regulatory\, and cost-efficiency challenges in this rapidly evolving field. \nAcross the three days\, you’ll get the chance to hear from KOLs like Ionis Pharmaceuticals\, AstraZeneca\, and CAMP4 Therapeutics as the present their data-driven case studies on managing quality\, regulatory affairs\, and cost-efficient manufacturing. \nDeep dive into the major challenges of streamlining analytical tools\, process development\, and look towards greener chemistries to ensure global uptake of oligonucleotide drugs. \nThis isn’t just an event\, it’s an investment in the future of your teams’ technical capabilities. Bringing together siRNA\, mRNA\, ASO\, oligo and oligo-conjugate developers\, this definitive summit fosters comprehensive development\, ensuring the resilience and longevity of this rapidly advancing modality. \nJoin us this August to assess the field\, take back actionable insights to your team\, and realize the potential of oligonucleotide therapeutics for prevalent diseases and improved market acceptance. \nEvent highlights: \n\n3 interactive workshops across CMC consideration\, oligo-conjugate analytical and detection methods\, and how to establish a robust control strategy\n18 data-driven case studies from complex oligo synthesis to scale-up and quality control. This is your end-to-end guide for oligo commercialization\n100+ industry experts across Analytical Development\, CMC and QC teams in attendance\, allowing you to connect\, benchmark and strive towards common goals together\n\nExpert speakers include: \n\nAngela Tsai\, Senior Manager – Collaboration & External Innovation\, Sanofi\nGeorge Bou-Assaf\, Associate Director\, Biogen\nHuijun Tian\, Director\, Analytical Development & Quality Control\, QurAlis\nIsaiah Cedillo\, Assistant Director – Manufacturing & Operations\, Ionis Pharmaceuticals\nJanine Tom\, Senior Principal Scientist\, Amgen\nSatya Kuchimanchi\, Senior Vice President\, Technical Operations\, Chemistry\, Manufacturing & Controls\, CAMP4 Therapeutics\n\n100+ Industry Experts | 3 Interactive Workshops | 20% Off Group Discounts | Data-Driven Case Studies \nTo know more visit: https://ter.li/eptndw
URL:https://www.pharmajournalist.com/event/3rd-oligonucleotide-cmc-analytical-development-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240903
DTEND;VALUE=DATE:20240906
DTSTAMP:20260516T013746
CREATED:20240515T145207Z
LAST-MODIFIED:20240515T145207Z
UID:39128-1725321600-1725580799@www.pharmajournalist.com
SUMMARY:3rd Cell Therapy Analytical Development Summit Europe
DESCRIPTION:Bringing together technical experts\, the 3rd Cell Therapy Analytical Development Summit Europe\, is the definitive summit dedicated to defining and refining analytics to ensure the swift progression of highly efficacious products through IND/IMPD and clinical trials. \nConnect with industry-leaders like Achilles Therapeutics\, Avobis Bio\, Bristol Myers Squibb\, Johnson & Johnson\, GSK\, MHRA\, to advance the future development of potent\, safe and effective cell therapies! \nJoin us in London for 3 days of exclusive content focused on providing the exclusive technical insights needed to take your product from characterisation to validation and release! \nAccess the full session details today.
URL:https://www.pharmajournalist.com/event/3rd-cell-therapy-analytical-development-summit-europe/
LOCATION:15Hatfields\, Chadwick Court\, London\, SE1 8DJ\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240909
DTEND;VALUE=DATE:20240911
DTSTAMP:20260516T013746
CREATED:20240613T144451Z
LAST-MODIFIED:20240613T144520Z
UID:39254-1725840000-1726012799@www.pharmajournalist.com
SUMMARY:Wearable Injectors and Connected Devices USA
DESCRIPTION:The Wearable Injectors and Connected Devices event is the only conference that discusses both wearable injectors and connected devices in one event. Over two days\, we bring together executives within the pharmaceutical industry to discuss the opportunities and challenges that face on-body devices\, and to collaborate on the future of the industry. The event provides and intimate environment to speak with experts and peers to learn from each other’s experiences\, and to meet with a variety of solutions providers working to supplement the industry. \nThe experience: \n\nA collaborative environment for pharma\, biotech and device developers to discuss the latest trends and challenges within the wearable injectors and connected device market.\nLearn from key industry players about new technologies\, strategies and processes for the development of wearable injectors.\nGain insights into the regulatory processes for the approval of wearable injectors and develop a greater understanding of how-to bring devices to market.\nCreate a dialogue with industry leaders for wearable injectors\, and develop a network with the key stake-holders in the market.\nDelve into the world of digital health and connectivity for the healthcare sector\, and discuss the future of connectivity for wearables.\nExamine the importance of usability for at home injectors\, and what is needed to make a device appropriate for patient administration.\n\nWhy attend: \n\n2 full days of networking opportunities.\n16+ sessions with 75% of speakers from big pharma companies\nAn agenda designed for professionals within the wearable injectors space\, focused on the development\, implementation and application of wearable injectors and connected devices.\nThe only conference discussing wearable injectors and connected devices together.
URL:https://www.pharmajournalist.com/event/wearable-injectors-and-connected-devices-usa-2024/
LOCATION:Boston\, USA
ORGANIZER;CN="SAE Media Group":MAILTO:EVENTS@SAEMEDIAGROUP.COM
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240909
DTEND;VALUE=DATE:20240911
DTSTAMP:20260516T013746
CREATED:20240719T115013Z
LAST-MODIFIED:20240719T115144Z
UID:39420-1725840000-1726012799@www.pharmajournalist.com
SUMMARY:ADC & TRP Pharma & Biotech Partnering Summit
DESCRIPTION:Major moves in pharma and biotech partnering are reshaping the landscape. For ADC companies\, the challenge lies in standing out\, validating their offerings\, and securing clinical-ready assets amidst this whirlwind of activity. \nHow does one differentiate and obtain assets poised for clinical success in the next wave of deals? \nEnter the ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit. \nVIEW THE FULL EVENT GUIDE \nWhy Attend? \n\nCuts through the noise of partnership events to gather a targeted critical mass of 100+ ADC companies\nProvides a platform for networking and fast-tracking the search and evaluation of earlier development assets\nEmpowers participants to navigate the complex partnering landscape with confidence by significantly improving the alignment\, efficiency\, and yield of conversations\n\nSecure your place here or get in touch with the team – info@hansonwade.com
URL:https://www.pharmajournalist.com/event/adc-trp-pharma-biotech-partnering-summit/
LOCATION:Revere Boston Common Hotel\, 200 Stuart Street\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com or Partnership Enquiries: sponsor@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240911
DTEND;VALUE=DATE:20240913
DTSTAMP:20260516T013746
CREATED:20240613T153308Z
LAST-MODIFIED:20240613T153308Z
UID:39264-1726012800-1726185599@www.pharmajournalist.com
SUMMARY:Pre-Filled Syringes Connect
DESCRIPTION:SAE Media Group are proud to announce the inaugural Pre-Filled Syringes Connect event taking place on the 11th and 12th of September in Boston. As a new addition to SAE’s leading injectable drug delivery portfolio\, PFS Connect will bring together device thought-leaders from big pharma\, biotech and device developers in an intimate\, relaxed and engaging setting\, fostering collaborations and idea exchanges crucial for driving innovation in injectable drug delivery. \nThe two-day agenda will bring you a series of keynote presentations and roundtable discussions facilitated by industry experts sharing their invaluable expertise and experiences around industry challenges and emerging trends allowing you to come away equipped with actionable knowledge to enhance your device development initiatives and strategic approach. Keynote presentations will also give you the chance gain insight into the latest case studies and innovations in the field. We hope to welcome you to this must attend event in September 2024! \nFree to attend for Pharma and Biotechs.
URL:https://www.pharmajournalist.com/event/pre-filled-syringes-connect/
LOCATION:Boston\, USA
ORGANIZER;CN="SAE Media Group":MAILTO:events@saemediagroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240917
DTEND;VALUE=DATE:20240921
DTSTAMP:20260516T013746
CREATED:20240513T102940Z
LAST-MODIFIED:20240513T102940Z
UID:39084-1726531200-1726876799@www.pharmajournalist.com
SUMMARY:9th CAR-TCR Summit
DESCRIPTION:The commercial success of cell therapies is continuing to grow! With a recent TIL approval\, a shift to earlier line CAR-T treatment\, and further approvals set for this year\, 2024 will be pivotal to demonstrate the clinical benefit of cell therapies and advance breakthroughs in solid tumors and autoimmunity. \nThat’s why now’s the time to join the 9th CAR-TCR Summit: the industry’s definitive forum committed to progressing end-to-end cell therapy development. This year’s 2-day conference will accommodate in-depth tracks covering Discovery\, Translation\, Clinical Development\, Early-Stage Manufacturing\, Late-Stage Manufacturing\, Analytical Development and Supply Chain & Clinical Operations. \nThis is your team’s one-stop shop for all functions to discover cutting-edge innovations\, significant clinical data and gain insights into how to conquer the bottlenecks withholding optimal durability\, accessibility\, safety and cost-efficiency. \nJoin 130+ expert speakers and 1\,000+ cell therapy experts to collaborate to achieve the shared goal of delivering these curative treatments to the ever-growing population of patients in need. \nTo see the speaker faculty\, what’s new for 2024\, full session details\, who you will meet and much more\, view the full agenda now: https://ter.li/wjnrky
URL:https://www.pharmajournalist.com/event/9th-car-tcr-summit/
LOCATION:Hynes Convention Center\, 900 Boylston St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240917
DTEND;VALUE=DATE:20240920
DTSTAMP:20260516T013746
CREATED:20240515T095715Z
LAST-MODIFIED:20240515T095715Z
UID:39116-1726531200-1726790399@www.pharmajournalist.com
SUMMARY:2nd CRISPR-Based Therapy Analytical Development Summit
DESCRIPTION:Develop\, characterize\, and validate robust analytical tools that demonstrate safety\, efficacy\, and regulatory compliance of genome editing therapies \nAs CRISPR-based therapies become ever-complex\, drug developers urgently need to innovate the analytical tools available to effectively characterize their safety and efficacy profiles and agree upon gold standards moving forward. We are also witnessing increased regulatory scrutiny\, with the FDA closely studying off-target analysis conducted ahead of the approval of Casgevy\, before finalizing guidance on genome editing therapies in January. \nTo keep up with these growing analytical demands\, the 2nd CRISPR-Based Therapy Analytical Development Summit is returning to unite 50+ key figures across Analytical Development\, CMC & QC domains\, all with the common goal of developing more precise\, accurate\, and sensitive analytical assays. \nExpert discussions will highlight analytical innovation with both traditional and disruptive CRISPR-based therapies\, and span in vivo and ex vivo delivery\, covering the following core themes: \n\nCharacterization of guides\, nucleases\, and full drug constructs\nRobust non-clinical and CMC assay development\, including biodistribution studies\, potency assays\, and on-/off- target sequencing detection\, nomination\, and prediction\nMeeting regulatory expectations for analytical data to support IND submissions successfully\n\nIf you are working to develop\, characterize\, and validate more robust analytical tools to enable the progression of your early R&D work into a clinical therapy\, this is your collaborative forum to equip you with the latest innovation\, case studies\, and actionable insights to level up your analytical efforts.
URL:https://www.pharmajournalist.com/event/2nd-crispr-based-therapy-analytical-development-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240917
DTEND;VALUE=DATE:20240920
DTSTAMP:20260516T013746
CREATED:20240530T075911Z
LAST-MODIFIED:20240530T075911Z
UID:39192-1726531200-1726790399@www.pharmajournalist.com
SUMMARY:3rd mRNA Process Development & Manufacturing Summit
DESCRIPTION:Your Roadmap for mRNA Process Development & Manufacturing with Optimized Purification\, Process Analytics & Enhanced Formulation to Improve Cost-Effectiveness & Scalability into the Clinic & Beyond \nThe mRNA manufacturing industry is experiencing a wave of innovation with the development of cancer vaccines\, emerging therapeutics\, and novel gene editing tools. Yet\, significant challenges remain – largely around the speed\, cost of production\, and limited flexibility to improve current processes with new technologies. \nReturning to Boston this September\, the 3rd mRNA Process Development & Manufacturing Summit has been carefully put together to address the industry’s most prominent pain points. Hear from 30+ expert speakers from the likes of BioNTech\, Merck & Co.\, Moderna\, Nutcracker Therapeutics\, Pfizer\, Sanofi\, Strand Therapeutics and more across three days of content spanning two tracks dedicated to Research Scale and IND-Enabling & Clinical Scale process development. \nBoost your mRNA drug substance to drug product by implementing high throughput process development\, optimizing mRNA synthesis and purification\, speeding up process analytics and innovating formulation to unlock the unlimited potential of mRNA for all applications. \n\nDates: September 17-19\, 2024\nLocation: Westin Boston Seaport District\, Boston\, MA\nEvent Program: https://ter.li/k46oir\n\nNew for 2024\, join the mRNA Purification focus day to enhance your upstream and downstream purification processes\, or dive into 3 pre-conference workshops to harness high throughput process development technology\, master mRNA process changes\, drug quality and patient safety\, and choose the right external partner. \nDownload the agenda here: https://ter.li/k46oir \nRegister your place here (and take advantage of group discounts of up to 20% when sending your team of three or more!): https://ter.li/wf4j0
URL:https://www.pharmajournalist.com/event/3rd-mrna-process-development-manufacturing-summit/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240917
DTEND;VALUE=DATE:20240920
DTSTAMP:20260516T013746
CREATED:20240618T121731Z
LAST-MODIFIED:20240618T121731Z
UID:39302-1726531200-1726790399@www.pharmajournalist.com
SUMMARY:2nd ADC Process Development Summit
DESCRIPTION:With cutting-edge strategies and industry insights\, the 2nd ADC Process Development Summit is back with a mission to boost conjugation yield\, optimize purification\, and streamline production to meet regulatory standards all whilst minimizing costs and timelines. \nJoin AstraZeneca\, Bristol Myers Squibb\, Pfizer and a community of industry experts in process development\, conjugation\, purification\, control\, CMC\, and engineering. With a focused discussion on process development challenges\, innovative solutions and practical takeaways\, leave equipped with the technical knowledge and connections to revolutionize your ADC manufacturing process. \nThis Summit is a must attend for everyone looking to increase conjugation yield and enhance TFF\, implement rigorous control strategies for superior drug substance quality\, develop scalable processes to cut unit operations\, accelerate production timelines\, and navigate regulatory landscapes with ease. \nDon’t miss this Summit\, where innovation meets implementation\, ensuring your ADC process development reaches its optimal efficacy and efficiency!
URL:https://www.pharmajournalist.com/event/2nd-adc-process-development-summit/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240924
DTEND;VALUE=DATE:20240927
DTSTAMP:20260516T013746
CREATED:20240704T165308Z
LAST-MODIFIED:20240704T165357Z
UID:39340-1727136000-1727395199@www.pharmajournalist.com
SUMMARY:6th RAS-Targeted Drug Development Summit
DESCRIPTION:The race to target the remaining RAS mutants continues\, with over 24 clinical and 70 pre-clinical stage programs striving for first- and best-in-class. Now more than ever\, we are witnessing this growing industry make strides to utilize novel modalities and elucidate mechanisms of resistance – making treating patients with RAS mutant cancers beyond NSCLC not just a possibility\, but a reality. \nAs the leading industry-centered forum\, the 6th RAS-Targeted Drug Development Summit 2024 returns to Boston this September and is once again dedicated to every aspect of discovery and development of RAS therapies\, from discovery through to clinical development\, to create effective frontline RAS therapies for cancer and better patient outcomes. \nOver three jam-packed days\, 38+ leading stakeholders will exhibit breakthrough novel data\, latest clinical advancements\, proof-of-concept\, and strategic perspectives\, all armed to improve the standard of care for patients in need. \nThis year’s summit will tackle some of the hottest advances and burning questions in the space\, such as: \n\nTargeting more mutants with RAS(ON) form\, pan-RAS approaches\, and non-canonical targets to combat cancers beyond NSCLC\nDefeating intrinsic or acquired mechanistic resistance and reducing off-target effects to ensure more effective RAS-directed medicines reach the patient\nShowcasing vaccines\, cell therapies\, monovalent and heterobifunctional modalities with improved selectivity and potency to avoid cancer recurrence\nInvestigating valuable combination approaches utilizing inhibitors of up- and downstream high-value targets such as SOS1\, MEK\, RAF\, and ERK\n\nJoin 200+ of your biopharma and academic peers from Early Discovery\, Translational Oncology\, and Clinical Development at the unrivaled end-to-end forum as we foster critical conversations and navigate cutting-edge treatments – empowering the developers of RAS-targeted therapies to make a positive impact on the future of cancer treatment. Join us as we work together to create effective frontline RAS therapies for better patient outcomes. \nTo know more visit: https://ter.li/hosjv6
URL:https://www.pharmajournalist.com/event/6th-ras-targeted-drug-development-summit/
LOCATION:Hilton Boston Park Plaza\, 50 Park Plaza\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR